HIV particles infecting a human T cell--Courtesy of NIH/NIAID Finding a cure for HIV has been a priority since its emergence in the 1980s, but the virus' ability to hide itself within...
A team led by the Duke Human Vaccine Institute and the National Institute of Allergy and Infectious Diseases has tracked the evolution of HIV and the body's corresponding immune response, hoping now to turn the knowledge gained into an experimental vaccine.
Johnson & Johnson's Janssen announced that a combination therapy of two intramuscular injections of HIV medications administered simultaneously monthly or bimonthly demonstrated comparability to a daily three-drug oral therapy during an ongoing Phase II trial.
Vaginal rings that release antiretroviral drugs to prevent AIDS hold promise in developing countries to stem the spread of the disease and empower women by allowing them to control their own drug regimens. And research communities are hailing two new trials in Africa for safety and efficacy.
A large study funded by the National Institutes of Health (NIH) found that a drug-delivering vaginal ring could protect some women against HIV. The results come on the heels of more promising data, which show that the ring device can reduce women's risk of developing the infection.
Antiretroviral treatments sometimes fail to work in people with HIV because of the virus' ability to "hide" in cells and then reemerge once therapy stops. Norway's Bionor tested anticancer drug romidepsin and a vaccine, Vacc-4x, in 17 HIV-positive patients in the hopes that the combo would force the virus out of hiding and then kill it.
China now counts more than half a million people with HIV/AIDS, and a new survey suggests that caseload reflects what could be a "hidden epidemic" in the Asia-Pacific region. Much of the recent increase is among adolescents.
A team at The Scripps Research Institute in La Jolla this week said they have identified four antibodies to target weaknesses in HIV, touting an "important advance" in HIV vaccine research that could assist in developing a vaccine.
Johnson & Johnson's Janssen announced that a Phase IIb study of a combination regimen of two investigational long-acting injectable HIV drugs found that the therapy performed similarly to a regimen consisting of three oral medications.
Roche is rolling out rapid tests for HIV, hepatitis C and hep C genotyping in Europe, continuing its molecular diagnostics winning streak a couple of weeks after scoring FDA approval for related tests and unveiling promising numbers for its testing business.